Farlosin SR Special Precautions

As with other alpha1-adrenoceptor antagonists, a reduction in blood pressure can occur in individual cases during treatment with Tamsulosin sustained release tablet 0.4 mg, as a result of which, rarely, syncope can occur. At the first signs of orthostatic hypotension (dizziness, weakness), the patient should sit or lie down until the symptoms have disappeared.
Before therapy with Tamsulosin sustained release tablet 0.4 mg is initiated, the patients should be examined in order to exclude the presence of other conditions, which can cause the same symptoms as benign prostatic hyperplasia. Digital rectum examination and, when necessary, determination of prostate specific antigen (PSA) should be performed before treatment and at regular intervals afterwards.
The treatment of patients with severe renal impairment (creatinine clearance of <10 ml/min) should be approached with caution, as these patients have not been studied.
The "Intraoperative Floppy Iris Syndrome" (IFIS, a variant of small pupil syndrome) has been observed during cataract and glaucoma surgery in some patients or on previously treated with tamsulosin hydrochloride. IFIS may increase the risk of eye complications during and after operation. Discontinuing tamsulosin hydrochloride 1-2 week prior to cataract or glaucoma surgery is anecdotally considered helpful, but the benefit of treatment discontinuation has not been established. IFIS has also been reported in patients who had discontinued tamsulosin for a longer period prior to the surgery.
The initiation of therapy with tamsulosin in patients for whom cataract or glaucoma surgery is scheduled is not recommended. During pre-operative assessment, surgeons and ophthalmic teams should consider whether patients scheduled for cataract or glaucoma surgery are being or have been treated with tamsulosin in order to ensure that appropriate measures will be in place to manage the IFIS during surgery.
Tamsulosin hydrochloride should not be given in combination with strong inhibitors of CYP3A4 in patients with poor metaboliser CYP2D6 phenotype.
Tamsulosin hydrochloride should be used with caution in combination with strong and moderate inhibitors of CYP3A4.
Cases of allergic reactions to tamsulosin in patients with a past history of sulfonamide allergy have been reported. If a patient reports a previously experienced sulfa allergy, caution is warranted when administrating tamsulosin hydrochloride.
It is possible that a remnant of the tablet is observed in the faeces.
Effect on Ability to Drive and Use Machines: No studies on the effects on the ability to drive and use machines have been performed. However, patients should be aware of the fact that dizziness, drowsiness, blurred vision and syncope can occur.